(Press-News.org) Statins may provide doctors with an unlikely new weapon with which to slow the progression of multiple sclerosis (MS).
No treatments can currently abate the advanced stage of the disease, known as secondary progressive MS, which gradually causes patients to become more disabled.
In a two-year clinical trial involving 140 patients with secondary progressive MS, the drug simvastatin slowed brain shrinkage, which is thought to contribute to patients' impairments. Supporting this finding, patients on simvastatin achieved better scores on movement tests and questionnaires that assess disability than patients taking a placebo.
MS is a neurological condition that affects around 2.3 million people worldwide. Most patients are initially diagnosed with relapsing-remitting MS, which causes periodic attacks. Around 65 per cent of people with relapsing remitting MS develop secondary progressive MS within 15 years of being diagnosed. The secondary progressive phase is where MS has the most personal and societal costs.
The authors of the new study, which was led by Imperial College London, said the findings were very encouraging, but would need to be replicated in a larger trial. The work is published today in the Lancet.
"At the moment, we don't have anything that can stop patients from becoming more disabled once MS reaches the progressive phase," said Dr Richard Nicholas, co-author of the study from the Department of Medicine at Imperial. "Discovering that statins can help slow that deterioration is quite a surprise. This is a promising finding, particularly as statins are already cheap and widely used.
"We need to do a bigger study with more patients, possibly starting in the earlier phase of the disease, to fully establish how effective it is," he added.
Dr Nicholas ran the trial with Dr Jeremy Chataway, then in the Department of Medicine at Imperial and now at University College London.
Statins are taken by millions of people to lower cholesterol and prevent heart disease, but it's unclear why they would have a beneficial effect on MS.
Some small studies have found a small benefit from statins in relapsing remitting MS, which is more treatable.
Secondary progressive MS has proven more challenging to alleviate. In 2013, cannabis became the latest drug to prove unsuccessful at slowing the progression of MS in a clinical trial.
This clinical trial is the culmination of long-standing research led by Professor John Greenwood at the UCL Institute of Ophthalmology showing the potential therapeutic benefits of using statins to treat autoimmune diseases such as multiple sclerosis and uveitis.
Professor Greenwood said, "After nearly two decades of research, it is immensely gratifying to see this work progress into the clinic to deliver benefits to patients."
INFORMATION:
The study was funded by J.P Moulton Foundation, Berkeley Foundation, Multiple Sclerosis Trials Collaboration, Rosetrees Trust and the National Institute for Health Research (NIHR).
For more information please contact:
Franca Davenport
Research Media Officer
Imperial College London
Email: f.davenport@imperial.ac.uk
Tel: +44(0)20 7594 2198
Out of hours duty press officer: +44(0)7803 886 248
Notes to editors
1. Reference: J. Chataway et al, 'Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial', The Lancet 383 (2014), doi: 10.1016/S0140-6736(13)62242-4
2. About Imperial College London
Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 14,000 students and 6,000 staff of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.
Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve global health, tackle climate change, develop sustainable sources of energy and address security challenges.
In 2007, Imperial College London and Imperial College Healthcare NHS Trust formed the UK's first Academic Health Science Centre. This unique partnership aims to improve the quality of life of patients and populations by taking new discoveries and translating them into new therapies as quickly as possible.
Website: http://www.imperial.ac.uk
3. About the National Institute for Health Research
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government's strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website.
Statins slow the progression of advanced multiple sclerosis in clinical trial
2014-03-19
ELSE PRESS RELEASES FROM THIS DATE:
Fried foods may interact with genes to influence body weight, say experts
2014-03-19
The results show that eating fried food more than four times a week had twice as big an effect on body mass index (BMI) for those with the highest genetic risk scores compared with lower scores. In other words, genetic makeup can inflate the effects of bad diet, says an accompanying editorial.
It is well known that both fried food consumption and genetic variants are associated with adiposity (fatness). However, the interaction between these two risk factors in relation to BMI and obesity has not been examined.
So a team of US researchers, led by Lu Qi, Assistant Professor ...
NHS sight tests lead to waste
2014-03-19
Michael Clarke, Consultant Ophthalmologist at Newcastle Eye Centre, says that apart from trauma and orthopaedics, ophthalmology receives more NHS outpatient referrals than any other speciality.
He says that opticians are constrained by legislation to refer patients to a medical practitioner if abnormalities are found at an NHS sight test. However, the testing done at NHS sight tests has become more complex and many patients are now referred with clinically insignificant abnormalities, leading to wastage of appointments in Hospital Eye Services.
So called 'Eye Health ...
Risk of obesity from regular consumption of fried foods may depend on genetic makeup
2014-03-19
Boston, MA —People with a genetic predisposition to obesity are at a higher risk of obesity and related chronic diseases from eating fried foods than those with a lower genetic risk, according to a new study from researchers from Harvard School of Public Health, Brigham and Women's Hospital, and Harvard Medical School. It is the first study to show that the adverse effects of fried foods may vary depending on the genetic makeup of the individual.
"Our study shows that a higher genetic risk of obesity may amplify the adverse effects of fried food consumption on body weight, ...
The Lancet: Statin may slow untreatable, progressive stage of multiple sclerosis
2014-03-19
Results of a phase 2 study published in The Lancet suggest that simvastatin, a cheap cholesterol lowering drug, might be a potential treatment option for the secondary progressive, or chronic, stage of multiple sclerosis (MS), which is currently untreatable.
Findings from the MS-STAT trial showed that a high, daily dose of simvastatin was safe, well tolerated, and slowed brain atrophy (shrinkage) by 43% over two years compared with placebo. Longitudinal studies suggest that atrophy progression is linked with disability.
In its early stages, MS is characterised by intermittent ...
Tamiflu® reduces risk of death by 25 percent in adults hospitalised with H1N1 pandemic influenza
2014-03-19
Adults hospitalised with H1N1 influenza during the 2009-2010 pandemic were 25% less likely to die from the disease if they were given antiviral drugs called neuraminidase inhibitors (NAIs) such as Tamiflu®, according to a large meta-analysis involving more than 29 000 patients from 38 countries, published in The Lancet Respiratory Medicine journal. The findings also indicate that treatment within 2 days of flu symptoms developing halved the risk of death compared with later treatment or no treatment.
"Many governments have stockpiles of Tamiflu that are close to expiry. ...
Increased adiposity and reduced physical activity in children: Cause or effect?
2014-03-18
Increased adiposity is likely to cause reduced physical activity in children, according to research published in this week's PLOS Medicine. The results of the study, conducted by Rebecca Richmond and colleagues from the MRC Integrative Epidemiology Unit at the University of Bristol, UK, suggest that promoting weight loss in overweight and obese children might also increase childhood activity levels.
Previous studies have shown an association between low physical activity and higher body mass index (BMI) in children but were not able to determine whether childhood adiposity ...
1 in 3 patients with bloodstream infections given inappropriate therapy
2014-03-18
DURHAM, N.C. -- Growing drug resistance, a high prevalence of S. aureus bacteria and ineffective antibiotics prescribed to one in three patients are among the challenges facing community hospitals in treating patients with serious bloodstream infections, according to researchers at Duke Medicine.
The findings, published March 18, 2014, in the journal PLOS ONE, provide the most comprehensive look at bloodstream infections in community hospitals to date. While the majority of people in need of medical care go to community hospitals, much of the existing research on bloodstream ...
Penn Medicine researchers show how lost sleep leads to lost neurons
2014-03-18
PHILADELPHIA - Most people appreciate that not getting enough sleep impairs cognitive performance. For the chronically sleep-deprived such as shift workers, students, or truckers, a common strategy is simply to catch up on missed slumber on the weekends. According to common wisdom, catch up sleep repays one's "sleep debt," with no lasting effects. But a new Penn Medicine study shows disturbing evidence that chronic sleep loss may be more serious than previously thought and may even lead to irreversible physical damage to and loss of brain cells. The research is published ...
Stem cells from muscle can repair nerve damage after injury, Pitt researchers show
2014-03-18
PITTSBURGH, March 18, 2014 – Stem cells derived from human muscle tissue were able to repair nerve damage and restore function in an animal model of sciatic nerve injury, according to researchers at the University of Pittsburgh School of Medicine. The findings, published online today in the Journal of Clinical Investigation, suggest that cell therapy of certain nerve diseases, such as multiple sclerosis, might one day be feasible.
To date, treatments for damage to peripheral nerves, which are the nerves outside the brain and spinal cord, have not been very successful, ...
Trends in food supplements differ from country to country, new study finds
2014-03-18
A new study, published today in the journal in PLOS ONE, shows which plant food supplements are most popular across Europe, with consumers using them to complement their diets or to maintain health.
The team of researchers from the Fundación para la Investigación Nutricional and the University of Surrey found that these products are taken in many different forms, including in tea, juice or by tablet. They analysed data from six European countries, collecting information from 2359 adult consumers of plant food supplements in Finland, Germany, Italy, Romania, Spain and ...